Novodiax, Inc.

Novodiax, Inc. is a California-based developer of rapid immunohistochemistry (IHC) and immunocytochemistry (ICC) assays and instrumentation for pathology and diagnostic testing. The company specializes in polymerized horseradish peroxidase (polyHRP) detection technology, enabling IHC results in as little as 10 minutes on frozen sections—significantly faster than conventional methods. Products include ihcDirect® assay kits (antibody-conjugated to polyHRP for direct staining), Q-STAIN® X automated histology instrument system, DewaxAR for FFPE (formalin-fixed, paraffin-embedded) tissue processing, and ancillary reagents. The ihcDirect product line serves both in vitro diagnostics (IVD) and research-use-only (RUO) markets, with expanding assay menus including melanoma markers (Mart-1), thyroid panels (CgA, CK19, Gal-3, PTH, TTF1, TROP2), and hematology markers (CD20, CD45, Pan-CK). The company targets pathologists, Mohs surgeons, and clinical laboratories requiring rapid intraoperative assessment and frozen-section analysis. Novodiax also offers contract research services including companion diagnostic development, target validation, antibody profiling, and custom bulk assay kit development for pharmaceutical and biotech partners. Operations are based in Hayward, California, with international sales and technical support capabilities. The company maintains a comprehensive literature center with instructions for use, reference publications, and remote/in-person technical support.